biopharmaceutical analysis

Biopharmaceutical Analysis: A Comprehensive Guide

Introduction:

The biopharmaceutical industry is booming, driving unprecedented demand for sophisticated analytical techniques to ensure drug safety, efficacy, and quality. This comprehensive guide delves into the multifaceted world of biopharmaceutical analysis, exploring the key techniques, challenges, and regulatory considerations involved in characterizing and qualifying these complex biological molecules. We'll journey from basic principles to advanced methodologies, equipping you with a solid understanding of this critical field. Whether you're a seasoned scientist or a curious newcomer, this post offers invaluable insights into the world of biopharmaceutical analysis.

1. Understanding Biopharmaceuticals: A Foundation for Analysis

Biopharmaceuticals, unlike traditional small-molecule drugs, are large, complex molecules derived from living organisms. This complexity presents unique analytical challenges. Understanding the nature of these molecules – including proteins, peptides, antibodies, and nucleic acids – is paramount to selecting the appropriate analytical techniques. We'll discuss the structural intricacies, post-translational modifications (PTMs), and inherent heterogeneity of biopharmaceuticals, highlighting their impact on analytical strategies. The differences between biosimilars and originator biologics will also be addressed, emphasizing the importance of rigorous comparative analytical testing.

1. Key Analytical Techniques in Biopharmaceutical Analysis

This section explores the core methodologies employed in biopharmaceutical characterization. We'll cover both established and emerging techniques, emphasizing their strengths and limitations.

Chromatography: High-performance liquid chromatography (HPLC), size-exclusion chromatography (SEC), and ion-exchange chromatography (IEC) are fundamental techniques for separating and purifying biomolecules. We'll discuss various detection methods, including UV, fluorescence, and mass spectrometry (MS)

detection, detailing their application in biopharmaceutical analysis.

Mass Spectrometry (MS): MS plays a crucial role in determining the molecular weight, identifying post-translational modifications, and characterizing impurities in biopharmaceuticals. We'll delve into different MS techniques, including electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI), and their application in various biopharmaceutical analyses.

Electrophoresis: Techniques like capillary electrophoresis (CE) and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) are employed to assess the purity, homogeneity, and aggregation state of biopharmaceuticals. We'll explore the principles and applications of these techniques, highlighting their advantages and disadvantages.

Spectroscopy: Techniques such as UV-Vis, circular dichroism (CD), and fluorescence spectroscopy provide valuable information on the conformation, stability, and interactions of biomolecules. We'll discuss their role in characterizing the secondary, tertiary, and quaternary structures of biopharmaceuticals.

1. Addressing the Challenges in Biopharmaceutical Analysis

Biopharmaceutical analysis is not without its challenges. The inherent complexity of these molecules, their susceptibility to degradation, and the need for high sensitivity and specificity demand meticulous analytical strategies. We'll explore key challenges, including:

Heterogeneity: Biopharmaceuticals often exhibit microheterogeneity due to PTMs, leading to variations in their structure and function. Addressing this heterogeneity requires sophisticated analytical techniques to characterize the different isoforms and their relative abundances.

Degradation: Biopharmaceuticals are susceptible to various degradation pathways, including oxidation, deamidation, and aggregation. Understanding these degradation pathways and developing strategies to minimize them is critical for ensuring product quality and stability.

Sensitivity and Specificity: Quantifying low levels of impurities and degradation products in biopharmaceuticals requires highly sensitive and specific analytical methods. We'll discuss the importance of method validation and the regulatory requirements for ensuring the accuracy and reliability of analytical data.

1. Regulatory Considerations and Quality Control

Regulatory agencies, such as the FDA and EMA, have stringent guidelines for biopharmaceutical analysis. These guidelines ensure product safety, efficacy, and consistency. We will discuss the key regulatory requirements for biopharmaceutical analysis, including:

Method Validation: Rigorous method validation is essential to demonstrate the accuracy, precision, specificity, and linearity of analytical methods. We'll outline the key parameters that need to be assessed during method validation.

Quality Control (QC): Robust QC procedures are vital to ensure the consistent quality of biopharmaceuticals throughout the manufacturing process. We'll discuss different QC tests and their role in ensuring product quality.

Stability Testing: Stability testing is crucial to determine the shelf life and storage conditions of biopharmaceuticals. We'll discuss various stability-indicating assays and their importance in evaluating product stability.

1. Future Trends in Biopharmaceutical Analysis

The field of biopharmaceutical analysis is constantly evolving. Emerging technologies and approaches are enhancing our ability to characterize these complex molecules with greater precision and efficiency. We'll explore some of these trends, including:

Advanced MS Techniques: Developments in MS, such as high-resolution MS and ion mobility spectrometry, are providing greater depth of characterization of biopharmaceuticals.

Automation and High-Throughput Screening: Automation and high-throughput screening methods are accelerating the analytical process and enabling faster drug development.

Data Analytics and Informatics: Advanced data analytics and informatics are crucial for interpreting the complex datasets generated by biopharmaceutical analysis.

Sample Book Outline:

Title: A Practical Guide to Biopharmaceutical Analysis

Introduction: Overview of biopharmaceuticals and their analytical challenges.
Chapter 1: Fundamentals of Biopharmaceutical Characterization: Structure, Function, and Heterogeneity.
Chapter 2: Chromatographic Techniques in Biopharmaceutical Analysis (HPLC, SEC, IEC).

Chapter 3: Mass Spectrometry in Biopharmaceutical Analysis (ESI, MALDI, etc.).
Chapter 4: Electrophoretic Techniques and Spectroscopy in Biopharmaceutical Analysis.
Chapter 5: Addressing Challenges: Degradation, Heterogeneity, and Impurity Analysis.
Chapter 6: Regulatory Guidelines and Quality Control in Biopharmaceutical Analysis.
Chapter 7: Advanced Techniques and Future Trends.
Conclusion: Summary and outlook for the field.

(Note: The following sections would expand on each chapter outlined above, providing detailed explanations and examples for each topic. Due to space limitations, a complete expansion of each chapter is not provided here. However, the previous sections of this blog post provide a foundation for such expansion.)

FAQs:

1. What is the difference between biosimilar and originator biologics? Biosimilars are highly similar to originator biologics but are not exact copies. Rigorous analytical testing is needed to demonstrate similarity.

1. What are post-translational modifications (PTMs)? PTMs are chemical modifications that occur after a protein is synthesized, affecting its structure and function. They pose analytical challenges due to heterogeneity.

1. What is method validation in biopharmaceutical analysis? It's a process to demonstrate that an analytical method is accurate, precise, specific, and reliable for its intended purpose.

1. What is the role of mass spectrometry in biopharmaceutical analysis? MS determines the molecular weight, identifies PTMs, and characterizes impurities.

1. What are the challenges in analyzing biopharmaceuticals? Heterogeneity,

degradation, and the need for high sensitivity and specificity.

1. What are some key regulatory considerations? Method validation, quality control, and stability testing.

1. What are emerging trends in biopharmaceutical analysis? Advanced MS techniques, automation, and data analytics.

1. What is the importance of stability testing? It determines the shelf life and appropriate storage conditions of a biopharmaceutical.

1. What types of chromatography are commonly used? HPLC, SEC, and IEC are frequently employed to separate and purify biomolecules.

Related Articles:

1. HPLC Method Development for Biopharmaceutical Analysis: Focuses on the practical aspects of developing and validating HPLC methods for biopharmaceutical analysis.

1. Mass Spectrometry in Biosimilar Characterization: Explores the specific applications of MS in comparing biosimilars to their originator biologics.

1. Overcoming Challenges in Biopharmaceutical Stability Testing: Provides solutions to common challenges encountered during biopharmaceutical stability studies.

1. Regulatory Requirements for Biopharmaceutical Analysis: A detailed

overview of FDA and EMA guidelines.

1. Advanced MS Techniques for Biopharmaceutical Characterization: A deep dive into cutting-edge MS technologies.

1. The Role of Data Analytics in Biopharmaceutical Analysis: Explores the use of advanced data analysis in handling large datasets.

1. Automation in Biopharmaceutical Analysis: A Review: Discusses the benefits and applications of automation in streamlining workflows.

1. Case Study: Analyzing a Novel Biopharmaceutical using a Multi-Analytical Approach: Presents a real-world example of biopharmaceutical analysis.

1. Biopharmaceutical Analysis: A Career Overview: Explores career paths and opportunities in the field.

biopharmaceutical analysis: Mass Spectrometry in Biopharmaceutical Analysis Igor A. Kaltashov, Shunhai Wang, Guanbo Wang, 2021-11-22 Biopharmaceuticals are a unique class of compounds due to their extreme structural complexity. The current text puts together a variety of the state-of-the art approaches that use mass spectrometry to evaluate various aspects of biopharmaceutical products ranging from monitoring stress-related structural changes to their quantitation in pharmacokinetic studies.

biopharmaceutical analysis: Design and Analysis of Subgroups with Biopharmaceutical Applications Naitee Ting, Joseph C. Cappelleri, Shuyen Ho, (Din) Ding-Geng Chen, 2020-05-01 This book provides an overview of the theories and applications on subgroups in the biopharmaceutical industry. Drawing from a range of expert perspectives in academia and industry, this collection offers an overarching dialogue about recent advances in biopharmaceutical applications, novel statistical and methodological developments, and potential future directions. The volume covers topics in subgroups in clinical trial design; subgroup identification and personalized medicine; and general issues in subgroup analyses, including regulatory ones. Included chapters present current methods, theories, and case applications in the diverse field of subgroup application and analysis. Offering timely perspectives from a range of authoritative sources, the volume is designed to have wide appeal to professionals in the pharmaceutical industry and to graduate students and

researchers in academe and government.

biopharmaceutical analysis: Biophysical Characterization of Proteins in Developing Biopharmaceuticals Damian J. Houde, Steven A. Berkowitz, 2019-11-13 Biophysical Characterization of Proteins in Developing Biopharmaceuticals, Second Edition, presents the latest on the analysis and characterization of the higher-order structure (HOS) or conformation of protein based drugs. Starting from the very basics of protein structure, this book explains the best way to achieve this goal using key methods commonly employed in the biopharmaceutical industry. This book will help today's industrial scientists plan a career in this industry and successfully implement these biophysical methodologies. This updated edition has been fully revised, with new chapters focusing on the use of chromatography and electrophoresis and the biophysical characterization of very large biopharmaceuticals. In addition, best practices of applying statistical analysis to biophysical characterization data is included, along with practical issues associated with the concept of a biopharmaceutical's developability and the technical decision-making process needed when dealing with biophysical characterization data. - Presents basic protein characterization methods and tools applicable to (bio)pharmaceutical research and development - Highlights the capabilities and limitations of each technique - Discusses the underlining science of each tool - Empowers industrial biophysical chemists by providing a roadmap for applying biophysical tools - Outlines the needs for new characterization and analytical tools in the biopharmaceutical industry

biopharmaceutical analysis: Biopharmaceutical Production Technology Ganapathy Subramanian, 2012-05-14 Cost-effective manufacturing of biopharmaceutical products is rapidly gaining in importance, while healthcare systems across the globe are looking to contain costs and improve efficiency. To adapt to these changes, industries need to review and streamline their manufacturing processes. This two volume handbook systematically addresses the key steps and challenges in the production process and provides valuable information for medium to large scale producers of biopharmaceuticals. It is divided into seven major parts: - Upstream Technologies - Protein Recovery - Advances in Process Development - Analytical Technologies - Quality Control - Process Design and Management - Changing Face of Processing With contributions by around 40 experts from academia as well as small and large biopharmaceutical companies, this unique handbook is full of first-hand knowledge on how to produce biopharmaceuticals in a cost-effective and quality-controlled manner.

biopharmaceutical analysis: Approaches to the Conformational Analysis of Biopharmaceuticals Roger L. Lundblad, 2009-12-15 The activity of many biopharmaceutical polymers is dependent on conformation, and the next several years will see increased interest in the conformational analysis of these polymers resulting from the development of biosimilar or follow-on biological products. While a wide variety of approaches to analysis exists, finding the most viable ones wou

biopharmaceutical analysis: Mass Spectrometry in Biopharmaceutical Analysis Igor A. Kaltashov, Guanbo Wang, Shunhai Wang, 2021-11-22 Biopharmaceuticals are a unique class of compounds due to their extreme structural complexity. The current text puts together a variety of the state-of-the art approaches that use mass spectrometry to evaluate various aspects of biopharmaceutical products ranging from monitoring stress-related structural changes to their quantitation in pharmacokinetic studies.

biopharmaceutical analysis: Approaches to the Purification, Analysis and Characterization of Antibody-Based Therapeutics Allan Matte, 2020-08-24 Approaches to the Purification, Analysis and Characterization of Antibody-Based Therapeutics provides the interested and informed reader with an overview of current approaches, strategies and considerations relating to the purification, analytics and characterization of therapeutic antibodies and related molecules. While there are obviously other books published in and around this subject area, they seem to be either older (c.a. year 2000 publication date) or are more limited in scope. The book will include an extensive bibliography of the published literature in the respective areas covered. It is not, however, intended to be a how-to methods book.

biopharmaceutical analysis: Analysis of Aggregates and Particles in Protein Pharmaceuticals Hanns-Christian Mahler, Wim Jiskoot, 2011-12-20 This book describes how to address the analysis of aggregates and particles in protein pharmaceuticals, provides a comprehensive overview of current methods and integrated approaches used to quantify and characterize aggregates and particles, and discusses regulatory requirements. Analytical methods covered in the book include separation, light scattering, microscopy, and spectroscopy.

biopharmaceutical analysis: Risk Management Applications in Pharmaceutical and Biopharmaceutical Manufacturing Hamid Mollah, Harold Baseman, Mike Long, 2013-03-18 Sets forth tested and proven risk management practices in drug manufacturing Risk management is essential for safe and efficient pharmaceutical and biopharmaceutical manufacturing, control, and distribution. With this book as their guide, readers involved in all facets of drug manufacturing have a single, expertly written, and organized resource to guide them through all facets of risk management and analysis. It sets forth a solid foundation in risk management concepts and then explains how these concepts are applied to drug manufacturing. Risk Management Applications in Pharmaceutical and Biopharmaceutical Manufacturing features contributions from leading international experts in risk management and drug manufacturing. These contributions reflect the latest research, practices, and industry standards as well as the authors' firsthand experience. Readers can turn to the book for: Basic foundation of risk management principles, practices, and applications Tested and proven tools and methods for managing risk in pharmaceutical and biopharmaceutical product manufacturing processes Recent FDA guidelines, EU regulations, and international standards governing the application of risk management to drug manufacturing Case studies and detailed examples demonstrating the use and results of applying risk management principles to drug product manufacturing Bibliography and extensive references leading to the literature and helpful resources in the field With its unique focus on the application of risk management to biopharmaceutical and pharmaceutical manufacturing, this book is an essential resource for pharmaceutical and process engineers as well as safety and compliance professionals involved in drug manufacturing.

biopharmaceutical analysis: State-Of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 2. Biopharmaceutical Characterization John E. Schiel, Darryl L. Davis, Oleg V. Borisov, Oleg Borisov, 2016-06-24 Distributed in print by Oxford University Press.

biopharmaceutical analysis: Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals Feroz Jameel, Susan Hershenson, 2010-07-13 A real-world guide to the production and manufacturing of biopharmaceuticals While much has been written about the science of biopharmaceuticals, there is a need for practical, up-to-date information on key issues at all stages of developing and manufacturing commercially viable biopharmaceutical drug products. This book helps fill the gap in the field, examining all areas of biopharmaceuticals manufacturing, from development and formulation to production and packaging. Written by a group of experts from industry and academia, the book focuses on real-world methods for maintaining product integrity throughout the commercialization process, clearly explaining the fundamentals and essential pathways for all development stages. Coverage includes: Research and early development phase appropriate approaches for ensuring product stability Development of commercially viable formulations for liquid and lyophilized dosage forms Optimal storage, packaging, and shipping methods Case studies relating to therapeutic monoclonal antibodies, recombinant proteins, and plasma fractions Useful analysis of successful and failed products Formulation and Process Development Strategies for Manufacturing Biopharma-ceuticals is an essential resource for scientists and engineers in the pharmaceutical and biotech industries, for government and regulatory agencies, and for anyone with an interest in the latest developments in the field.

biopharmaceutical analysis: Preclinical Safety Evaluation of Biopharmaceuticals Joy A. Cavagnaro, 2013-03-07 The goal is to provide a comprehensive reference book for the preclinicaldiscovery and development scientist whose responsibilities span target identification, lead

candidate selection, pharmacokinetics, pharmacology, and toxicology, and for regulatory scientists whose responsibilities include the evaluation of novel therapies. —From the Afterword by Anthony D. Dayan Proper preclinical safety evaluation can improve the predictive value, lessen the time and cost of launching new biopharmaceuticals, and speed potentially lifesaving drugs to market. This guide covers topics ranging from lead candidate selection to establishing proof of concept and toxicity testing to the selection of the first human doses. With chapters contributed by experts in their specific areas, Preclinical Safety Evaluation of Biopharmaceuticals: A Science-Based Approach to Facilitating Clinical Trials: Includes an overview of biopharmaceuticals with information on regulation and methods of production Discusses the principles of ICH S6 and their implementation in the U.S., Europe, and Japan Covers current practices in preclinical development and includes a comparison of safety assessments for small molecules with those for biopharmaceuticals Addresses all aspects of the preclinical evaluation process, including: the selection of relevant species; safety/toxicity endpoints; specific considerations based upon class; and practical considerations in the design, implementation, and analysis of biopharmaceuticals Covers transitioning from preclinical development to clinical trials This is a hands-on, straightforward reference for professionals involved in preclinical drug development, including scientists, toxicologists, project managers, consultants, and regulatory personnel.

biopharmaceutical analysis: Single-Use Technology in Biopharmaceutical Manufacture Regine Eibl, Dieter Eibl, 2019-07-18 Authoritative guide to the principles, characteristics, engineering aspects, economics, and applications of disposables in the manufacture of biopharmaceuticals The revised and updated second edition of Single-Use Technology in Biopharmaceutical Manufacture offers a comprehensive examination of the most-commonly used disposables in the manufacture of biopharmaceuticals. The authors—noted experts on the topic—provide the essential information on the principles, characteristics, engineering aspects, economics, and applications. This authoritative guide contains the basic knowledge and information about disposable equipment. The author also discusses biopharmaceuticals' applications through the lens of case studies that clearly illustrate the role of manufacturing, quality assurance, and environmental influences. This updated second edition revises existing information with recent developments that have taken place since the first edition was published. The book also presents the latest advances in the field of single-use technology and explores topics including applying single-use devices for microorganisms, human mesenchymal stem cells, and T-cells. This important book: • Contains an updated and end-to-end view of the development and manufacturing of single-use biologics • Helps in the identification of appropriate disposables and relevant vendors • Offers illustrative case studies that examine manufacturing, quality assurance, and environmental influences • Includes updated coverage on cross-functional/transversal dependencies, significant improvements made by suppliers, and the successful application of the single-use technologies Written for biopharmaceutical manufacturers, process developers, and biological and chemical engineers, Single-Use Technology in Biopharmaceutical Manufacture, 2nd Edition provides the information needed for professionals to come to an easier decision for or against disposable alternatives and to choose the appropriate system.

biopharmaceutical analysis: PAT Applied in Biopharmaceutical Process Development And Manufacturing Cenk Undey, Duncan Low, Jose C. Menezes, Mel Koch, 2011-12-07 As with all of pharmaceutical production, the regulatory environment for the production of therapeutics has been changing as a direct result of the US FDA-initiated Quality by Design (QbD) guidelines and corresponding activities of the International Committee for Harmonization (ICH). Given the rapid growth in the biopharmaceutical area and the complexity of the molecules, the optimum use of which are still being developed, there is a great need for flexible and proactive teams in order to satisfy the regulatory requirements during process development. Process Analytical Technologies (PAT) applied in biopharmaceutical process development and manufacturing have received significant attention in recent years as an enabler to the QbD paradigm. PAT Applied in Biopharmaceutical Process Development and Manufacturing covers technological advances in

measurement sciences, data acquisition, monitoring, and control. Technical leaders present real-life case studies in areas including measuring and monitoring raw materials, cell culture, purification, and cleaning and lyophilization processes via advanced PAT. They also explore how data are collected and analyzed using advanced analytical techniques such as multivariate data analysis, monitoring, and control in real-time. Invaluable for experienced practitioners in PAT in biopharmaceuticals, this book is an excellent reference guide for regulatory officials and a vital training aid for students who need to learn the state of the art in this interdisciplinary and exciting area.

biopharmaceutical analysis: *The Oxford Handbook of the Economics of the Biopharmaceutical Industry* Patricia M. Danzon, Sean Nicholson, 2012-04-12 The biopharmaceutical industry has been a major driver of technological change in health care, producing unprecedented benefits for patients, cost challenges for payers, and profits for shareholders. As consumers and companies benefit from access to new drugs, policymakers around the globe seek mechanisms to control prices and expenditures commensurate with value. More recently the 1990s productivity boom of new products has turned into a productivity bust, with fewer and more modest innovations, and flat or declining revenues for innovative firms as generics replace their former blockbuster products. This timely volume examines the economics of the biopharmaceutical industry, with eighteen chapters by leading academic health economists. Part one examines the economics of biopharmaceutical innovation including determinants of the costs and returns to new drug development; how capital markets finance R&D and how costs of financing the biopharmaceutical industry compare to financing costs for other industries; the effects of safety and efficacy regulation by the Food and Drug Administration (FDA) and of price and reimbursement regulation on incentives for innovation; and the role of patents and regulatory exclusivities. Part two examines the market for biopharmaceuticals with chapters on prices and reimbursement in the US, the EU, and other industrialized countries, and in developing countries. It looks at the optimal design of insurance for drugs and the effects of cost sharing on spending and on health outcomes; how to measure the value of pharmaceuticals using pharmacoeconomics, including theory, practical challenges, and policy issues; how to measure pharmaceutical price growth over time and recent evidence; empirical evidence on the value of pharmaceuticals in terms of health outcomes; promotion of pharmaceuticals to physicians and consumers; the economics of vaccines; and a review of the evidence on effects of mergers, acquisitions and alliances. Each chapter summarizes the latest insights from theory and recent empirical evidence, and outlines important unanswered questions and areas for future research. Based on solid economics, it is nevertheless written in terms accessible to the general reader. The book is thus recommended reading for academic economists and non-economists, and for those in industry and policy who wish to understand the economics of this fascinating industry.

biopharmaceutical analysis: Biopharmaceutical Manufacturing Gary Gilleskie, Charles Rutter, Becky McCuen, 2021-09-07 Biopharmaceuticals, medicines made by or from living organisms (including cells from living organisms), are extremely effective in treating a broad range of diseases. Their importance to human health has grown significantly over the years as more biopharmaceutical products have entered the market, and now the biggest selling drugs in the world are biopharmaceuticals. Biopharmaceutical Manufacturing: Principles, Processes and Practices provides concise, comprehensive, and up-to-date coverage of biopharmaceutical manufacturing. Written in a clear and informal style, the content has been influenced by the authors' substantial industry experience and teaching expertise. That expertise enables the authors to address the many questions posed over the years both by university students and professionals with experience in the field. Consequently, the book will appeal both to undergraduate or graduate students using it as a textbook and specialized industry practitioners seeking to understand the big picture of biopharmaceutical manufacturing. This book:

biopharmaceutical analysis: *Biosimilars* Hiten J. Gutka, Harry Yang, Shefali Kakar, 2018-12-13 This book provides a comprehensive overview of the biosimilar regulatory framework, the development process and clinical aspects for development of biosimilars. The development path

of a biosimilar is just as unique as a development path of a new drug, tailored by the mechanism of action, the quality of the molecule, published information on the reference product, the current competitive environment, the target market and regulatory guidance, and most importantly, the emerging totality of evidence for the proposed biosimilar during development. For the ease of readers, the book comprises of six sections as follows: Section I: Business, Health Economics and Intellectual Property Landscape for Biosimilars Section II: Regulatory Aspects of Development and Approval for Biosimilars Section III: Biopharmaceutical Development and Manufacturing of Biosimilars Section IV: Analytical Similarity Considerations for Biosimilars Section V: Clinical aspects of Biosimilar Development Section VI: Biosimilars- Global Development and Clinical Experience Chapters have been written by one or more experts from academia, industry or regulatory agencies who have been involved with one or more aspects of biosimilar product development. The authors and editors have an expertise in commercialization and pricing of biosimilars, intellectual property considerations for biosimilars, chemistry manufacturing controls (CMC) and analytical development for biosimilars, regulatory and clinical aspects of biosimilar development. Besides the industry practitioners, the book includes several contributions from regulators across the globe.

biopharmaceutical analysis: An Essential Guide to Biopharmaceuticals David Aebisher, 2020 This book provides a current review of the field of biopharmaceutical pharmacology. Biopharmaceuticals are drugs obtained in biotechnological processes using living organisms such as bacteria and fungi. An analysis was performed from biochemical and physiological point of view. This book covers an essential guide to current knowledge and analysis of biopharmaceuticals (Chapter 1-5). The composition of the biopharmaceuticals is provided. In this book we also discuss the historical point of view of the use of archeological botany, medicinal plants, strategies and main advances in communication between the nature and the advances of biopharmacy (Chapter 6-8). This book reports results from experimental and clinical work (Chapter 9). The book includes data regarding the therapy in combination with chemotherapeutic agents.

biopharmaceutical analysis: *Biopharmaceutical Applied Statistics Symposium* Karl E. Peace, Ding-Geng Chen, Sandeep Menon, 2018-08-21 This BASS book Series publishes selected high-quality papers reflecting recent advances in the design and biostatistical analysis of biopharmaceutical experiments – particularly biopharmaceutical clinical trials. The papers were selected from invited presentations at the Biopharmaceutical Applied Statistics Symposium (BASS), which was founded by the first Editor in 1994 and has since become the premier international conference in biopharmaceutical statistics. The primary aims of the BASS are: 1) to raise funding to support graduate students in biostatistics programs, and 2) to provide an opportunity for professionals engaged in pharmaceutical drug research and development to share insights into solving the problems they encounter. The BASS book series is initially divided into three volumes addressing: 1) Design of Clinical Trials; 2) Biostatistical Analysis of Clinical Trials; and 3) Pharmaceutical Applications. This book is the second of the 3-volume book series. The topics covered include: Statistical Approaches to the Meta-analysis of Randomized Clinical Trials, Collaborative Targeted Maximum Likelihood Estimation to Assess Causal Effects in Observational Studies, Generalized Tests in Clinical Trials, Discrete Time-to-event and Score-based Methods with Application to Composite Endpoint for Assessing Evidence of Disease Activity-Free , Imputing Missing Data Using a Surrogate Biomarker: Analyzing the Incidence of Endometrial Hyperplasia, Selected Statistical Issues in Patient-reported Outcomes, Network Meta-analysis, Detecting Safety Signals Among Adverse Events in Clinical Trials, Applied Meta-analysis Using R, Treatment of Missing Data in Comparative Effectiveness Research, Causal Estimands: A Common Language for Missing Data, Bayesian Subgroup Analysis with Examples, Statistical Methods in Diagnostic Devices, A Question-Based Approach to the Analysis of Safety Data, Analysis of Two-stage Adaptive Seamless Trial Design, and Multiplicity Problems in Clinical Trials – A Regulatory Perspective.

biopharmaceutical analysis: Capillary Gel Electrophoresis Andras Guttman, László Hajba, 2021-12-04 Capillary Gel Electrophoresis and Related Microseparation Techniques covers all

theoretical and practical aspects of capillary gel electrophoresis. It also provides an excellent overview of the key application areas of nucleic acid, protein and complex carbohydrate analysis, affinity-based methodologies, micropreparative aspects and related microseparation methods. It not only gives readers a better understanding of how to utilize this technology, but also provides insights into how to determine which method will provide the best technical solutions to particular problems. This book can also serve as a textbook for undergraduate and graduate courses in analytical chemistry, analytical biochemistry, molecular biology and biotechnology courses. - Covers all theoretical and practical aspects of capillary gel electrophoresis - Excellent overview of the key applications of nucleic acid, protein and complex carbohydrate analysis, affinity-based methodologies, micropreparative aspects and related microseparation methods - Teaches readers how to use the technology and select methods that are ideal for fundamental problems - Can serve as a textbook for undergraduate and graduate courses in analytical chemistry, analytical biochemistry, molecular biology and biotechnology courses

biopharmaceutical analysis: *Pharmacokinetics and Pharmacodynamics of Biotech Drugs* Bernd Meibohm, 2006-12-13 This first ever coverage of the pharmacokinetic and pharmacodynamic characteristics of biopharmaceuticals meets the need for a comprehensive book in this field. It spans all topics from lead identification right up to final-stage clinical trials. Following an introduction to the role of PK and PD in the development of biotech drugs, the book goes on to cover the basics, including the pharmacokinetics of peptides, monoclonal antibodies, antisense oligonucleotides, as well as viral and non-viral gene delivery vectors. The second section discusses such challenges and opportunities as pulmonary delivery of proteins and peptides, and the delivery of oligonucleotides. The final section considers the integration of PK and PD concepts into the biotech drug development plan, taking as case studies the preclinical and clinical drug development of tasidotin, as well as the examples of cetuximab and pegfilgrastim. The result is vital reading for all pharmaceutical researchers.

biopharmaceutical analysis: Stem Cell Drugs - A New Generation of Biopharmaceuticals Phuc Van Pham, 2018-10-25 This invaluable resource discusses the current revolution in stem cell-based drugs and their potential use in clinical applications. Each chapter is contributed by a pre-eminent scientist in the field. An introductory section presents current stem cell drugs and stem cell-based products and a discussion of production, quality control, mechanisms, and efficacy. Following sections include discussions on stem cell-derived microvesicles based products, and derived exosomes based products. Stem Cell Drugs - A New Generation of Biopharmaceuticals and the other books in the Stem Cells in Clinical Applications series are invaluable to scientists, researchers, advanced students and clinicians working in stem cells, regenerative medicine or tissue engineering. This groundbreaking volume is also essential reading for those researching or studying drug development or pharmaceutical science.

biopharmaceutical analysis: *Statistical Design and Analysis in Pharmaceutical Science* Shein-Chung Chow, Jen-pei Liu, 2018-10-03 Offers a comprehensive, unified presentation of statistical designs and methods of analysis for all stages of pharmaceutical development--emphasizing biopharmaceutical applications and demonstrating statistical techniques with real-world examples.

biopharmaceutical analysis: The Challenge of CMC Regulatory Compliance for Biopharmaceuticals John Geigert, 2019-05-08 Biopharmaceuticals (i.e., biological medicines sourced from genetically-engineered living systems) for treatment of human diseases have become a significant percentage of the pharmaceutical industry. And not just the recombinant DNA-derived proteins and monoclonal antibodies (both from the innovators and biosimilars); but now, an increasing awareness of the importance of gene therapy and genetically engineered cellular medicinal products. These biopharmaceuticals are being developed by many companies whose Chemistry, Manufacturing & Control (CMC) teams have varying degrees of familiarity or experience with the CMC strategy and regulatory compliance requirements for these challenging products. Companies clearly plan out the strategy for their clinical study plans, but frequently, the

development of a strategy for CMC is an afterthought. Coupled with the complexity of the biopharmaceutical manufacturing processes and products, and this can be a recipe for disaster. The third edition of this book provides insights and practical guidance for the CMC teams to develop an acceptable cost-effective, risk-based CMC regulatory compliance strategy for all biopharmaceuticals (recombinant proteins, monoclonal antibodies, genetically engineered viruses and genetically engineered human cells) from early clinical stage development through market approval. The third edition of this book provides added coverage for the biosimilars, antibody drug conjugates (ADCs), bispecific antibodies, genetically engineered viruses, and genetically engineered cells. This third edition of the book also addresses the heightened pressure on CMC regulatory compliance timelines due to the introduction of expedited clinical pathways moving the clinical development closer to a seamless phase process (e.g., FDA Breakthrough Therapy designation, CBER Regenerative Medicine Advanced Therapy (RMAT) designation, EMA Priority Medicines (PRIME) designation). The Challenge of CMC Regulatory Compliance for Biopharmaceuticals is essential, practical information for all pharmaceutical development scientists, Manufacturing and Quality Unit staff, Regulatory Affairs personnel, and senior management involved in the manufacture of biopharmaceuticals.

biopharmaceutical analysis: Continuous Biopharmaceutical Processes David Pfister, Lucrèce Nicoud, Massimo Morbidelli, 2018-10-11 Provides a coherent and critical view on the potential benefits of various continuous processes in the biopharmaceutical industry.

biopharmaceutical analysis: *Design and Analysis of Subgroups with Biopharmaceutical Applications* , 2020 This book provides an overview of the theories and applications on subgroups in the biopharmaceutical industry. Drawing from a range of expert perspectives in academia and industry, this collection offers an overarching dialogue about recent advances in biopharmaceutical applications, novel statistical and methodological developments, and potential future directions. The volume covers topics in subgroups in clinical trial design; subgroup identification and personalized medicine; and general issues in subgroup analyses, including regulatory ones. Included chapters present current methods, theories, and case applications in the diverse field of subgroup application and analysis. Offering timely perspectives from a range of authoritative sources, the volume is designed to have wide appeal to professionals in the pharmaceutical industry and to graduate students and researchers in academe and government.

biopharmaceutical analysis: *Process Validation in Manufacturing of Biopharmaceuticals* Gail Sofer, 2000-03-24 A study of biopharmaceutical process validation. It aims to enable developers and producers to ensure safe products, reduce the risk of adverse reactions in patients, and avoid recalls by outlining sophisticated validation approaches to characterize processes, process intermediates, and final product fully. The text emphasizes cost effectiveness wh

biopharmaceutical analysis: Membrane Processing for Dairy Ingredient Separation Kang Hu, James Dickson, 2015-07-20 Membrane processing is a filtration technique in which particles are separated from liquids by being forced through a porous material, or membrane. Applied to dairy products, the separation techniques allow valuable compounds, found in milk, to be isolated for use as ingredients in food processing. A comprehensive overview of membrane separation processes, this book explores various applications such as pressure driven processes, electrical field driven processes, and concentration driven processes, for the recovery of various dairy streams and ingredients. The topics covered place emphasis on new applications, including microfiltration, ultrafiltration, reverse osmosis, electrodialysis, and pervaporation. The text also presents in-depth knowledge of the mechanisms of each membrane separation process, as well as membrane types and the equipment used in these processes. Combining their educational backgrounds and substantial industrial experience in dairy ingredients processes, the authors address cutting-edge technologies that have been thoroughly researched and have great potential to be commercialized in the near future. The book will therefore be of interest to dairy industry professionals and will serve as a source of reference material for professors and students in food science and engineering.

biopharmaceutical analysis: *Biopharmaceutical Applied Statistics Symposium* Karl E. Peace,

Ding-Geng Chen, Sandeep Menon, 2018-09-03 This BASS book Series publishes selected high-quality papers reflecting recent advances in the design and biostatistical analysis of biopharmaceutical experiments – particularly biopharmaceutical clinical trials. The papers were selected from invited presentations at the Biopharmaceutical Applied Statistics Symposium (BASS), which was founded by the first Editor in 1994 and has since become the premier international conference in biopharmaceutical statistics. The primary aims of the BASS are: 1) to raise funding to support graduate students in biostatistics programs, and 2) to provide an opportunity for professionals engaged in pharmaceutical drug research and development to share insights into solving the problems they encounter. The BASS book series is initially divided into three volumes addressing: 1) Design of Clinical Trials; 2) Biostatistical Analysis of Clinical Trials; and 3) Pharmaceutical Applications. This book is the third of the 3-volume book series. The topics covered include: Targeted Learning of Optimal Individualized Treatment Rules under Cost Constraints, Uses of Mixture Normal Distribution in Genomics and Otherwise, Personalized Medicine – Design Considerations, Adaptive Biomarker Subpopulation and Tumor Type Selection in Phase III Oncology Trials, High Dimensional Data in Genomics; Synergy or Additivity - The Importance of Defining the Primary Endpoint, Full Bayesian Adaptive Dose Finding Using Toxicity Probability Interval (TPI), Alpha-recycling for the Analyses of Primary and Secondary Endpoints of Clinical Trials, Expanded Interpretations of Results of Carcinogenicity Studies of Pharmaceuticals, Randomized Clinical Trials for Orphan Drug Development, Mediation Modeling in Randomized Trials with Non-normal Outcome Variables, Statistical Considerations in Using Images in Clinical Trials, Interesting Applications over 30 Years of Consulting, Uncovering Fraud, Misconduct and Other Data Quality Issues in Clinical Trials, Development and Evaluation of High Dimensional Prognostic Models, and Design and Analysis of Biosimilar Studies.

biopharmaceutical analysis: Biopharmaceuticals Ming-Kung Yeh, Yuan-Chuan Chen, 2018-09-19 Biopharmaceuticals are derived from biological sources, either live organisms or their active components; nowadays, they are mainly produced by biotechnologies. Biopharmaceuticals are extensively used in the treatment of various diseases such as cardiovascular, metabolic, neurological diseases, cancer, and others for which there are no available therapeutic methods. With the advance of science, biopharmaceuticals have revolutionized the treatment, prevention, and diagnosis of many patients with disabling and life-threatening diseases. Innovative biopharmaceuticals definitely improve the life quality of patients and enhance the effectiveness of the healthcare system. This book encompasses the discovery, production, application, and regulation of biopharmaceuticals to demonstrate their research achievement, prospects, and challenges. We expect the significance of biopharmaceuticals to be revealed and emphasized by this book.

biopharmaceutical analysis: Biopharmaceuticals Gary Walsh, 2013-04-29 The latest edition of this highly acclaimed textbook, provides a comprehensive and up-to-date overview of the science and medical applications of biopharmaceutical products. Biopharmaceuticals refers to pharmaceutical substances derived from biological sources, and increasingly, it is synonymous with 'newer' pharmaceutical substances derived from genetic engineering or hybridoma technology. This superbly written review of the important areas of investigation in the field, covers drug production, plus the biochemical and molecular mechanisms of action together with the biotechnology of major biopharmaceutical types on the market or currently under development. There is also additional material reflecting both the technical advances in the area and detailed information on key topics such as the influence of genomics on drug discovery.

biopharmaceutical analysis: *Quality by Design for Biopharmaceutical Drug Product Development* Feroz Jameel, Susan Hershenson, Mansoor A. Khan, Sheryl Martin-Moe, 2015-04-01 This volume explores the application of Quality by Design (QbD) to biopharmaceutical drug product development. Twenty-eight comprehensive chapters cover dosage forms, liquid and lyophilized drug products. The introductory chapters of this book define key elements of QbD and examine how these elements are integrated into drug product development. These chapters also discuss lessons learned from the FDA Office of Biotechnology Products pilot program. Following chapters demonstrate how

QbD is used for formulation development ranging from screening of formulations to developability assessment to development of lyophilized and liquid formats. The next few chapters study the use of small-scale and surrogate models as well as QbD application to drug product processes such as drug substance freezing and thawing, mixing, sterile filtration, filling, lyophilization, inspection and shipping and handling. Later chapters describe more specialized applications of QbD in the drug product realm. This includes the use of QbD in primary containers, devices and combination product development. The volume also explores QbD applied to vaccine development, automation, mathematical modeling and monitoring, and controlling processes and defining control strategies. It concludes with a discussion on the application of QbD to drug product technology transfer as well as overall regulatory considerations and lifecycle management. Quality by Design for Biopharmaceutical Drug Product Development is an authoritative resource for scientists and researchers interested in expanding their knowledge on QbD principles and uses in creating better drugs.

biopharmaceutical analysis: Innovative Statistics in Regulatory Science Shein-Chung Chow, 2019-11-14 Statistical methods that are commonly used in the review and approval process of regulatory submissions are usually referred to as statistics in regulatory science or regulatory statistics. In a broader sense, statistics in regulatory science can be defined as valid statistics that are employed in the review and approval process of regulatory submissions of pharmaceutical products. In addition, statistics in regulatory science are involved with the development of regulatory policy, guidance, and regulatory critical clinical initiatives related research. This book is devoted to the discussion of statistics in regulatory science for pharmaceutical development. It covers practical issues that are commonly encountered in regulatory science of pharmaceutical research and development including topics related to research activities, review of regulatory submissions, recent critical clinical initiatives, and policy/guidance development in regulatory science. Devoted entirely to discussing statistics in regulatory science for pharmaceutical development. Reviews critical issues (e.g., endpoint/margin selection and complex innovative design such as adaptive trial design) in the pharmaceutical development and regulatory approval process. Clarifies controversial statistical issues (e.g., hypothesis testing versus confidence interval approach, missing data/estimands, multiplicity, and Bayesian design and approach) in review/approval of regulatory submissions. Proposes innovative thinking regarding study designs and statistical methods (e.g., n-of-1 trial design, adaptive trial design, and probability monitoring procedure for sample size) for rare disease drug development. Provides insight regarding current regulatory clinical initiatives (e.g., precision/personalized medicine, biomarker-driven target clinical trials, model informed drug development, big data analytics, and real world data/evidence). This book provides key statistical concepts, innovative designs, and analysis methods that are useful in regulatory science. Also included are some practical, challenging, and controversial issues that are commonly seen in the review and approval process of regulatory submissions. About the author Shein-Chung Chow, Ph.D. is currently a Professor at Duke University School of Medicine, Durham, NC. He was previously the Associate Director at the Office of Biostatistics, Center for Drug Evaluation and Research, United States Food and Drug Administration (FDA). Dr. Chow has also held various positions in the pharmaceutical industry such as Vice President at Millennium, Cambridge, MA, Executive Director at Covance, Princeton, NJ, and Director and Department Head at Bristol-Myers Squibb, Plainsboro, NJ. He was elected Fellow of the American Statistical Association and an elected member of the ISI (International Statistical Institute). Dr. Chow is Editor-in-Chief of the Journal of Biopharmaceutical Statistics and Biostatistics Book Series, Chapman and Hall/CRC Press, Taylor & Francis, New York. Dr. Chow is the author or co-author of over 300 methodology papers and 30 books.

biopharmaceutical analysis: Mathematical and Statistical Skills in the Biopharmaceutical Industry Arkadiy Pitman, Oleksandr Sverdlov, L. Bruce Pearce, 2019-07-15 Mathematical and Statistical Skills in the Biopharmaceutical Industry: A Pragmatic Approach describes a philosophy of efficient problem solving showcased using examples pertinent to the

biostatistics function in clinical drug development. It was written to share a quintessence of the authors' experiences acquired during many years of relevant work in the biopharmaceutical industry. The book will be useful will be useful for biopharmaceutical industry statisticians at different seniority levels and for graduate students who consider a biostatistics-related career in this industry. Features: Describes a system of principles for pragmatic problem solving in clinical drug development. Discusses differences in the work of a biostatistician in small pharma and big pharma. Explains the importance/relevance of statistical programming and data management for biostatistics and necessity for integration on various levels. Describes some useful statistical background that can be capitalized upon in the drug development enterprise. Explains some hot topics and current trends in biostatistics in simple, non-technical terms. Discusses incompleteness of any system of standard operating procedures, rules and regulations. Provides a classification of scoring systems and proposes a novel approach for evaluation of the safety outcome for a completed randomized clinical trial. Presents applications of the problem solving philosophy in a highly problematic transfusion field where many investigational compounds have failed. Discusses realistic planning of open-ended projects.

biopharmaceutical analysis: Biotechnology and Biopharmaceuticals , 2013-12-16 Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs, Second Edition addresses the pivotal issues relating to translational science, including preclinical and clinical drug development, regulatory science, pharmaco-economics and cost-effectiveness considerations. The new edition also provides an update on new proteins and genetic medicines, the translational and integrated sciences that continue to fuel the innovations in medicine, as well as the new areas of therapeutic development including cancer vaccines, stem cell therapeutics, and cell-based therapies.

biopharmaceutical analysis: *A Lifecycle Approach to Knowledge Excellence in the Biopharmaceutical Industry* Nuala Calnan, Martin J Lipa, Paige E. Kane, Jose C. Menezes, 2017-06-26 This book addresses the rapidly emerging field of Knowledge Management in the pharmaceutical, medical devices and medical diagnostics industries. In particular, it explores the role that Knowledge Management can play in ensuring the delivery of safe and effective products to patients. The book also provides good practice examples of how the effective use of an organisation's knowledge assets can provide a path towards business excellence.

biopharmaceutical analysis: *Measuring Elemental Impurities in Pharmaceuticals* Robert Thomas, 2018-01-29 Recent regulations on heavy metal testing have required the pharmaceutical industry to monitor a suite of elemental impurities in pharmaceutical raw materials, drug products and dietary supplements. These new directives s are described in the new United States Pharmacopeia (USP) Chapters , , and , together with Q3D, Step 4 guidelines for elemental impurities, drafted by the ICH (International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use), a consortium of global pharmaceutical associations, including the European Pharmacopeia (Ph.Eur.), the Japanese Pharmacopeia (JP) and the USP. This book provides a complete guide to the analytical methodology, instrumental techniques and sample preparation procedures used for measuring elemental impurities in pharmaceutical and nutraceutical materials. It offers readers the tools to better understand plasma spectrochemistry to optimize detection capability for the full suite of elemental PDE (Permitted Daily Exposure) levels in the various drug delivery categories. Other relevant information covered in the book includes: The complete guide to measuring elemental impurities in pharmaceutical and nutraceutical materials. Covers heavy metals testing in the pharmaceutical industry from an historical perspective. Gives an overview of current USP Chapters and and ICH Q3D Step 4 Guidelines. Explains the purpose of validation protocols used in Chapter , including how J-values are calculated Describes fundamental principles and practical capabilities of ICP-MS and ICP-OES. Offers guidelines about the optimum strategy for risk assessment Provides tips on how best to prepare and present your data for regulatory inspection. An indispensable resource, the fundamental principles and practical benefits of ICP-OES and ICP-MS are covered in a

reader-friendly format that a novice, who is carrying out elemental impurities testing in the pharmaceutical and nutraceutical communities, will find easy to understand.

biopharmaceutical analysis: Healthcare Biotechnology Dimitris Dogramatzis, 2016-04-19 Foreseeing and planning for all of the possibilities and pitfalls involved in bringing a biotechnology innovation from inception to widespread therapeutic use takes strong managerial skills and a solid grounding in biopharmaceutical research and development procedures. Unfortunately there has been a dearth of resources for this aspect of the field.

biopharmaceutical analysis: Cell Culture Engineering Gyun Min Lee, Helene Faustrup Kildegaard, 2020-01-13 Offers a comprehensive overview of cell culture engineering, providing insight into cell engineering, systems biology approaches and processing technology In Cell Culture Engineering: Recombinant Protein Production, editors Gyun Min Lee and Helene Faustrup Kildegaard assemble top class authors to present expert coverage of topics such as: cell line development for therapeutic protein production; development of a transient gene expression upstream platform; and CHO synthetic biology. They provide readers with everything they need to know about enhancing product and bioprocess attributes using genome-scale models of CHO metabolism; omics data and mammalian systems biotechnology; perfusion culture; and much more. This all-new, up-to-date reference covers all of the important aspects of cell culture engineering, including cell engineering, system biology approaches, and processing technology. It describes the challenges in cell line development and cell engineering, e.g. via gene editing tools like CRISPR/Cas9 and with the aim to engineer glycosylation patterns. Furthermore, it gives an overview about synthetic biology approaches applied to cell culture engineering and elaborates the use of CHO cells as common cell line for protein production. In addition, the book discusses the most important aspects of production processes, including cell culture media, batch, fed-batch, and perfusion processes as well as process analytical technology, quality by design, and scale down models. -Covers key elements of cell culture engineering applied to the production of recombinant proteins for therapeutic use -Focuses on mammalian and animal cells to help highlight synthetic and systems biology approaches to cell culture engineering, exemplified by the widely used CHO cell line -Part of the renowned Advanced Biotechnology book series Cell Culture Engineering: Recombinant Protein Production will appeal to biotechnologists, bioengineers, life scientists, chemical engineers, and PhD students in the life sciences.

biopharmaceutical analysis: Bayesian Analysis with R for Drug Development Harry Yang, Steven Novick, 2019-06-26 Drug development is an iterative process. The recent publications of regulatory guidelines further entail a lifecycle approach. Blending data from disparate sources, the Bayesian approach provides a flexible framework for drug development. Despite its advantages, the uptake of Bayesian methodologies is lagging behind in the field of pharmaceutical development. Written specifically for pharmaceutical practitioners, Bayesian Analysis with R for Drug Development: Concepts, Algorithms, and Case Studies, describes a wide range of Bayesian applications to problems throughout pre-clinical, clinical, and Chemistry, Manufacturing, and Control (CMC) development. Authored by two seasoned statisticians in the pharmaceutical industry, the book provides detailed Bayesian solutions to a broad array of pharmaceutical problems. Features Provides a single source of information on Bayesian statistics for drug development Covers a wide spectrum of pre-clinical, clinical, and CMC topics Demonstrates proper Bayesian applications using real-life examples Includes easy-to-follow R code with Bayesian Markov Chain Monte Carlo performed in both JAGS and Stan Bayesian software platforms Offers sufficient background for each problem and detailed description of solutions suitable for practitioners with limited Bayesian knowledge Harry Yang, Ph.D., is Senior Director and Head of Statistical Sciences at AstraZeneca. He has 24 years of experience across all aspects of drug research and development and extensive global regulatory experiences. He has published 6 statistical books, 15 book chapters, and over 90 peer-reviewed papers on diverse scientific and statistical subjects, including 15 joint statistical works with Dr. Novick. He is a frequent invited speaker at national and international conferences. He also developed statistical courses and conducted training at the FDA and USP as well as Peking

University. Steven Novick, Ph.D., is Director of Statistical Sciences at AstraZeneca. He has extensively contributed statistical methods to the biopharmaceutical literature. Novick is a skilled Bayesian computer programmer and is frequently invited to speak at conferences, having developed and taught courses in several areas, including drug-combination analysis and Bayesian methods in clinical areas. Novick served on IPAC-RS and has chaired several national statistical conferences.

Additional Resources

biopharmaceutical analysis

Biopharmaceutical Analysis

Biopharmaceutical Analysis

Related Articles

- biology principles and explorations answer key
- biologycorner com cellular respiration answer key
- blue ridge wellness photos

Back to Home